Tech Company Financing Transactions
SeLux Diagnostics Funding Round
On 3/16/2022, SeLux Diagnostics raised $50 million in Series C investment from RA Capital, Northpond Ventures and Sands Capital Management.
Transaction Overview
Company Name
Announced On
3/16/2022
Transaction Type
Venture Equity
Amount
$50,000,000
Round
Series C
Investors
RA Capital (Lead Investor) (Peter Kolchinsky)
Proceeds Purpose
This Series C funding allows us to build out our commercial team and positions Selux to transform infectious diseases patient care by establishing NGP as the new standard.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
56 Roland St. 206
Charlestown, MA 02129
USA
Charlestown, MA 02129
USA
Phone
Website
Email Address
Overview
SeLux Diagnostics is developing a Next Generation Phenotyping (NGP) platform that promises to transform infectious disease patient treatment by dramatically increasing the speed and accuracy with which targeted, personalized antibiotic therapies can be prescribed.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Steve Lufkin
Chief Scientific Officer
Benjamin Spears
Chief Technical Officer
Eric Stern
President
Aleksandar Vacic
VP - Engineering
Nathan Purmort
Browse more venture capital transactions:
Prev: 3/16/2022: Quadric.io venture capital transaction
Next: 3/16/2022: Ex Parte venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on tech company VC transactions. VC transactions on this site are sourced from publicly available VC deal announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs